Tatsuo Yata

Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice

Masayuki Suzuki, Kiyofumi Honda, Masanori Fukazawa et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 166 citations

Medicine, Pharmacology, Pharmacotherapy +17

Reduction of Serum Cholesterol Levels Alters Lesional Composition of Atherosclerotic Plaques

Masashi Shiomi, Takashi Ito, Toyohiro Tsukada et al. · Arteriosclerosis Thrombosis and Vascular Biology · 1995 · 128 citations · Full text

Medicine, Cardiology, Pathology +17

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models

M. Suzuki, Minako Takeda, A Kito et al. · Nutrition and Diabetes · 2014 · 97 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Cell compositions of coronary and aortic atherosclerotic lesions in WHHL rabbits differ. An immunohistochemical study.

Masashi Shiomi, Takashi Ito, Toyohiro Tsukada et al. · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · 1994 · 75 citations · Full text

Veterinary Medicine, Pathobiology, Pathology +16

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats

Takumi Nagata, Masanori Fukazawa, Kiyofumi Honda et al. · American Journal of Physiology-Endocrinology and Metabolism · 2012 · 44 citations

Medicine, Pharmacology, Pharmacotherapy +15